Sorry! There are no upcoming events in this category. Please check this page again later.

It has now been over six months since the FDA authorized Paxlovid ... metallic taste in the mouth. In clinical trials, 5.6 percent of patients who received Paxlovid experienced dysgeusia.

The two partners have revealed the first clinical data from a phase 2b trial of a personalised vaccine ... we can improve on the rates of recurrence-free survival achieved by PD-1 blockade in ...